Future analyses are required to determine whether compounds such as E-2-dodecenal can rescue epilepsy-associated KCNQ2–R213 or arrhythmia-associated KCNQ1–R243 mutant channels or if the mutation precludes binding and/or functional efficacy as we observed for KCNQ2–R213A. This evidence concerns the gene KCNQ2 and epilepsy.